http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2024, Vol. 33 ›› Issue (6): 495-510.DOI: 10.5246/jcps.2024.06.037

• Original articles • Previous Articles     Next Articles

Preparation of core-shell targeted tracer recombinant human interleukin II microspheres via coaxial electrostatic spraying

Yuan Zhu1, Jiaqi Xu1, Xiaoyan Chen1, Yingshu Feng3, Caleb Kesse Firempong1, Haibing He4,5,*(), Hongfei Liu1,2,4,*()   

  1. 1 College of Pharmacy, Jiangsu University, Zhenjiang 212013, Jiangsu, China
    2 Jiangsu Sunan Pharmaceutical Industrial Co., Ltd., Zhenjiang 212400, Jiangsu, China
    3 Zhenjiang Key Laboratory of Functional Chemistry, Institute of Medicine & Chemical Engineering, Zhenjiang College, Zhenjiang 212028, Jiangsu, China
    4 Jiangsu Haizhihong Biomedical Co., Ltd., Nantong 226001, Jiangsu, China
    5 Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China
  • Received:2024-02-06 Revised:2024-02-25 Accepted:2024-03-29 Online:2024-06-30 Published:2024-06-30
  • Contact: Haibing He, Hongfei Liu
  • Supported by:
    2023 Nantong Jianghai Talent Plan (Grant No. 2023A053), the 2021 Zhenjiang Sixth ‘169 Project’ Scientific Research Project, the 2021 Jurong Social Development Science & Technology Program (Grant No. ZA42109), the 2022 New Drugs and Platform Enhancement Project of the Yangtze Delta Drug Advanced Research Institute, the Zhenjiang Science and Technology Project (Grant No. SH2020048), the China Postdoctoral Science Foundation (Grant No. 2020M681532), the Jiangsu Planned Projects for Postdoctoral Research Funds (Grant No. 2020Z209), and the Natural Science Research Projects of Universities in Jiangsu Province (Grant No. 20KJD350001).

Abstract:

The potential application of recombinant human interleukin-2 (rhIL-2) in promoting immune cell proliferation and differentiation for the treatment of lung cancer is acknowledged. However, the inherent challenges associated with the short half-life and instability of rhIL-2 necessitate its encapsulation into microspheres for sustained release administration. In this study, the coaxial electrostatic spray technique was employed to fabricate rhIL-2-loaded core-shell microspheres. Quantum dots served as tracer materials, and the core-shell composite microspheres were fashioned with chitosan coating the rhIL-2 and quantum dots conjugates in the core layer and hyaluronic acid in the shell layer. A systematic exploration of factors such as carrier concentration, positive voltage, pinhole diameter, and spray flow rate was conducted using a single-factor method. The coaxial electrostatic spray process parameters for core-shell microsphere preparation were also meticulously optimized. The results indicated that the developed core-shell microspheres exhibited a favorable particle size ranging from 1.2 to 2.0 μm, accompanied by encapsulation efficiency and drug loading values of 78.39% ± 1.96% and 19.58 ± 2.76 μg/mg, respectively. In vitro release studies demonstrated a sustained release effect without any discernible burst release phenomenon. Biological activity assessments revealed that rhIL-2 within the core-shell microspheres mirrored the efficacy of the free protein drug. Additionally, in vivo imaging analysis attested to the active targeting properties of the microspheres. These findings robustly supported the successful development of sustained-release targeted rhIL-2-loaded microspheres, providing a theoretical foundation for protein-microsphere formulations.

Key words: Coaxial spray, Quantum dots, Hyaluronic acid, Microspheres

Supporting: